P&T COMMUNITY
 
MediMedia Managed Markets
Our
Other
Journal
Managed Care magazine
Login / Register
Join Us  Facebook  Twitter  Linked In
About P&T Journal
Contacts:
Editorial: Sonja Sherritze, Editor
Advertising: Maureen Dwyer Liberti,
    Vice President, Group Publisher

Production: Mary Ellen Curry,
    Director of Production Services

Circulation: Jackie Ott, Circulation Manager


Statement of Purpose
Guidelines for Authors
Masthead
Editorial Board
Reprints


Recent Issues

July 2012

Features

Editorial

Hydrocodone Rescheduling Amendment and Pipeline Products on the Horizon

A controversial bill to change the classification of the opioid hydrocodone from Schedule III to Schedule II might help decrease the incidence of drug abuse through stricter regulation of Schedule II products, or, as some groups claim, it might hinder access for patients with legitimate prescriptions.
Jennifer A. Gershman, PharmD, CPh; and Andrea D. Fass, PharmD

Therapy for Stable Angina in Women

Mortality rates for cardiovascular disease are higher in women than in men, but studies of women have been conducted less frequently. Current pharmacological and nonpharmacological treatment options for women with stable angina are reviewed.
Raheleh Sarbaziha, MD; Tara Sedlak, MD; Chrisandra Shufelt, MD, MS; Puja K. Mehta, MD; and C. Noel Bairey Merz, MD

Controversies in Practice

Hydroxyprogesterone Caproate Injection (Makena) One Year Later

To Compound or Not to Compound—That Is the Question

Preterm births have increased by 27% over the last decade in the U.S. The main ingredient in Makena, 17P, is less expensive at compounding pharmacies, but this method is not FDA-approved. The authors discuss the quality, safety, and use of Makena and compounded 17P; the potential for liability; cost considerations; and recommended restrictions for the product’s use.
Yesha Patel, PharmD; and Martha M. Rumore, PharmD, JD

Continuing Education Credit

A Review of Abuse-Deterrent Opioids for Chronic Nonmalignant Pain

Chronic nonmalignant pain, which affects millions of people, is the most common reason patients seek medical care. Both current and potential opioid analgesics are discussed, along with new technologies used to prevent abuse.
Robin Moorman-Li, PharmD, BCACP; Carol A. Motycka, PharmD, BCACP; Lisa D. Inge, PharmD, BCPS, BCACP, AAHIVE; Jocelyn Myrand Congdon, PharmD; Susan Hobson, PharmD; and Brian Pokropski, PharmD

Departments

Medication Errors

Physical Environments That Promote Safe Medication Use

The physical design of an organization’s workspace can enhance or diminish patient safety.
Matthew Grissinger, RPh, FaScP

Prescription: Washington

FDA's New Authority on Drug Shortages

Drug companies may be required to report shortages sooner, but the FDA legislation still lacks power.
Stephen Barlas

New Drugs/Drug News/New Medical Devices

FDA approvals, drug indications, and updates

Pharmaceutical Approval Update

Tazarotene (Fabior Foam) for acne; estradiol valerate and estradiol valerate/dienogest (Natazia) for heavy menstrual bleeding; and taliglucerase alfa (Elelyso) for Gaucher’s disease
Marvin M. Goldenberg, PhD, RPh, MS

Drug Forecast

Fospropofol Disodium (Lusedra) Injection for Anesthesia-Care Sedation

A Clinical Review

Fospropofol disodium (Lusedra) for anesthesia sedation
Ramy Boules, PharmD; Andrew Szkiladz, PharmD; and Anna Nogid, BS, PharmD, BCPS